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Background: To prevent clinical relapse in teenagers with inflammatory bowel disease (IBD) there is a need to
monitor disease activity continuously. Timely optimisation of medical treatment may nip a preclinical relapse in the
bud and change the natural course of IBD. Traditionally, disease monitoring is done during scheduled visits, but this
is when most teenagers report full control. IBD care could be more efficient if patients were seen at times of clinical
need. This study aims to examine the effectiveness of a web-assisted calprotectin-based treatment algorithm
(IBD-live) compared with usual practices in teenagers with IBD.
Methods/design: A randomized trial of web-based disease monitoring versus usual care is conducted at 10 Dutch
IBD care centers. We plan to recruit 180 patients between 10- and 19-years old with quiescent IBD at baseline.
Teenagers assigned to IBD-live will use the flarometer -an automatic cumulation of disease activity and fecal calprotectin
measurements- to estimate probability of relapse. In case the flarometer indicates high risk the patient requires treatment
intensification in accordance with national guidelines; low risk means that maintenance therapy is unchanged; and
intermediate risk requires optimisation of drug adherence. Patients assigned to usual practice get the best accepted
medical care with regular health checks. Primary outcome is the frequency of relapse at 52 weeks of follow-up. The
diagnosis of relapse is based on a clinical activity index score >10 points necessitating remission induction therapy.
Secondary outcomes include quality of life and cost-effectiveness.
Discussion: Web-assisted monitoring of disease activity with rapid access for those with acute relapse may allow
teenagers to develop skills that are required of adult patients (including communication and self-determination). Similar
monitoring systems have been introduced for teenagers with asthma and diabetes, with a positive effect on disease
control, but the intervention has not been evaluated in teenagers with IBD. A randomized trial in adult patients with
ulcerative colitis showed that a web-assisted treatment algorithm is feasible, safe and cost-effective. Results of the
current trial are expected to have important implications for teenagers with IBD that incurs substantial health burdens
and economic costs.
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Inflammatory bowel diseae (IBD) includes two major
forms of intestinal inflammation: Crohn’s disease and ul-
cerative colitis. In both types inflammation waxes and
wanes over time in an unpredictable fashion. Treatment
of children and adolescents with IBD is aimed at indu-
cing and maintaining remission of disease activity to
ensure normal growth and pubertal development, and
improving the quality of life of patients. To prevent re-
lapses there is need for continuous monitoring of disease
activity for timely optimisation of medical treatment.
Twenty five per cent of the total IBD cases present in
childhood or adolescence [1], and the incidence is in-
creasing [2–4]. In the Netherlands each year approxi-
mately 250 teenagers are diagnosed with IBD [5]. Health
professionals confronted with the increased disease bur-
den may be interested in finding ways to ease the pres-
sure on overstretched clinics with new approaches to
monitor disease activity in IBD.Existing knowledge
Endoscopy is the standard for assessing intestinal inflam-
mation [6], but the invasive nature of the procedure limits
its use for routine evaluation of disease activity. Intensi-
fication of treatment in teenagers is therefore guided by
regular use of clinical composite scores including the
Pediatric Crohn’s Disease Activity Index (PCDAI) [7] and
the Pediatric Ulcerative Colitis Activity Index (PUCAI)
[8]. When used as stand-alone tests these scores may be
subject to bias. High scores may reflect relapse, but could
also be caused by gastrointestinal symptoms not related to
IBD, such as irritable bowel syndrome. Moreover, under-
reporting the symptom burden is a characteristic coping
strategy for teenagers during a face-to-face conversation
with a physician [9]. Traditionally, many clinicians use
C-reactive protein (CRP) as an objective add-on test to
monitor disease activity [10].Fig. 1 Flarometer home monitoring strategy and treatment algorithmFecal calprotectin (fCal) is a noninvasive marker of
inflammation that correlates well with endoscopic and
histopathological disease activity [11]. Measuring fCal is
a useful screening tool for identifying patients who are
most likely to need endoscopy for suspected IBD [12].
We assessed the value of periodic CRP and fCal testing
to predict early relapse in teenagers with confirmed IBD
[13]. We followed 62 patients who claimed to have no
symptoms and found that fCal levels increase prior to
CRP and before manifestations of clinical symptoms.
The positive predictive value to detect early relapse was
40 % with CRP and 60 % with fCal testing. We con-
cluded that fCal is a better add-on test to monitor dis-
ease activity than CRP. Periodic use of fCal could help
to identify teenagers who require treatment intensifica-
tion at the time of minimal disease rather than at the
time of clinically overt relapse.
Home monitoring of disease activity and treatment
algorithm
The above described “Full Control Study” [13] provided
evidence that disease activity scores and fCal measure-
ments are the best combination to predict relapse
in teenagers who are doing well. Building on this we
designed a relapse risk stratification tool (flarometer,
Figure 1) that can be used at home. The flarometer is
an automatic cumulation of patients’ answers to dis-
ease activity questionnaires (PUCAI or the short ver-
sion of the PCDAI (shPCDAI) [14], which excludes
blood test results). After completion of these question-
naires the web application asks the patient to send a
stool sample to the Department of Laboratory Medi-
cine of the University Medical Centre Groningen,
where it is analysed for fCal with a rapid test. In case
the PUCAI or shPCDAI indicates moderate to severe
disease activity, the patient is automatically advised
not to await the stool result, but to immediately con-
tact the local IBD-team. The stool result is entered
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tion, and a customized clinical alert is transmitted to
the patient and local IBD-team. The advice will vary
with the position of the pointer on the flarometer
scale. When the pointer is in the high-risk stratum,
clinical relapse is highly suspected and the local IBD-
team is advised to intensify treatment in accordance
with national guidelines [15]. In the low-risk stratum
maintenance therapy remains unchanged and an alert
to use the flarometer will be sent in three months. In
the intermediate range, drug adherence is optimised
and the flarometer will be used again in a month. After
two consecutive intermediate results the local IBD-
team is advised to intensify treatment (Fig. 2).
Need for a trial
Web-assisted monitoring of disease activity with rapid
access for those with acute relapse may allow teenagers
to develop skills that are required of adult patients
(including communication and self-determination) [16].
A randomized trial in adult patients with ulcerative col-
itis showed that a web-assisted treatment algorithm is
feasible, safe and cost-effective compared to usual care.
The intervention increased compliance and quality of
life, and reduced healthcare costs [17]. Web-based dis-
ease monitoring has been introduced for teenagers with
asthma [18] and diabetes [19], with a positive effect on
disease control, but the intervention has not been evalu-
ated in teenagers with IBD.
The trial described in this protocol aims to examine
the efficacy of a web-assisted calprotectin-based treat-
ment algorithm, compared with usual practice, on dis-
ease course among teenagers with IBD. This project will
move IBD care for teenagers into a new era, from trad-
itional paternalism (the doctor at the wheel) to a phase
in which teenagers take ownership of their chronic dis-
ease and participate in the therapeutic decision-making
process (teenagers at the wheel). Informing teenagers
periodically about fCal results may enable them to
understand better the importance of adherence. StudiesFig. 2 Graphical representation of flarometer test frequency and treatment
local IBD-team is advised to intensify treatment and remeasure in one mon
and an alert to use the flarometer will be sent in three months. In the inte
be used again in a month. After two consecutive intermediate results the l
at eight months. IBD Inflammatory bowel diseasein adults report that 30–45 % of patients do not use
maintenance drugs regularly [20], and nonadherence
among teenagers is even higher [21]. Nonadherent pa-
tients have an increased risk of clinical relapse [22] and
generate greater annual health care costs than adherent
patients [23]. Furthermore, the IBD-team could be used
more efficiently if patients were seen at times of clinical
need, instead of during three-monthly routine visits.
Choice of comparator
Treatment in the group assigned to usual practices rep-
resents the currently best-accepted IBD care. For teen-
agers with IBD in remission this means regular checks at
the outpatient clinic as before the trial. A health check
includes a physicians’ rating of disease activity and blood
sampling. In case of clinical relapse the patient is advised
to intensify treatment in accordance with national guide-
lines [15]. When a patient experiences a relapse between
two regular health checks, rapid access to specialist care
is provided.
Study objectives
We aim to compare the effect of treatment delivered ac-
cording to a web-assisted calprotectin-based algorithm
(IBD-live) against the same treatment delivered according
to usual practice.
We hypothesize that use of IBD-live may reduce the re-
lapse rate during a 52-week follow-up period. Furthermore,
we postulate that users of IBD-live have higher scores on
the disease specific quality of life IMPACT-III question-
naire, and that use of IBD-live is accompanied by lower
costs of disease management as compared to usual care.
Trial design
This trial is designed as a randomized, controlled, open
label multicenter superiority strategy trial with two paral-
lel groups. For allocation concealment, randomization will
be carried out using a separate list of computer-generated
random allocation numbers for each participating center
(involving permuted blocks with a ratio of 1:1 allocation).advice. In the high-risk stratum, clinical relapse is suspected and the
th. In the low-risk stratum, maintenance therapy remains unchanged
rmediate range, drug adherence is optimised and the flarometer will
ocal IBD-team is advised to intensify treatment. This scenario is shown
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outcomes
Study setting
Study participants will be recruited from six tertiary care
centers in the Netherlands (Groningen, Amsterdam (2x),
Rotterdam, Utrecht and Leiden), and from four large
general teaching hospitals (The Hague, Zwolle, Enschede
and Arnhem). The principal investigators at the various
sites are members of the Kids with Crohn’s and Colitis
(KiCC) working group for Collaborative Research in the
Netherlands. Together they treat about two-thirds of the
total pediatric IBD population in the Netherlands.
Since 2007 national treatment guidelines for IBD are
in use that have provided uniformity in treatment [15].
Immunomodulation with thiopurines is the first choice
in patients with Crohn’s disease. In case of failure or in-
tolerance methotrexate can be used. In ulcerative colitis
the first choice is aminosalicylate monotherapy. Thio-
purine co-medication is recommended in those with fre-
quently relapsing disease. Teenagers with active Crohn’s
are treated with steroids and gradual dose tapering, or
with an exclusive oral polymeric diet for six weeks. Pa-
tients with active ulcerative colitis are treated with ste-
roids and aminosalicylate dose escalation. Anti-tumor
necrosis factor (TNF) antibodies are labeled for use after
failure of conventional therapy (step-up).
Inclusion and exclusion criteria for participants
Approximately 10 % of teenagers with IBD will have a
severe disease course and require use of the complete
arsenal of available therapies in a limited period of time
to maintain remission. We aim to include the other
90 % of teenagers with a more stable disease course.
Eligible patients are those: 10- to 19-years old, with
quiescent IBD for more than three months before study
enrollment, with IBD diagnosed according to the Porto
criteria [24] more than six months before enrollment,
who have access to internet, with knowledge of the
Dutch language, and with an adult caregiver who is will-
ing to actively support participation.
Potential participants will be excluded from the study if
any of the following conditions occur: maintenance treat-
ment with infliximab or adalimumab (for unavoidable fre-
quent contact with health providers); presence of ileostomy
or ileoanal pouch (as fCal cut-off is not validated for small
bowel feces); or any comorbidity at the time of enrollment
that requires hospitalization or frequent blood sampling.
Interventions
Teenagers assigned to the experimental arm of the trial
have access to all modules of the web-based portal: (1)
the flarometer, an automatic cumulation of an online
patient rated PUCAI or shPCDAI, and the result of a
fCal point of care test (Quantum Blue® Calprotectin,Bühlmann Laboratories AG, Schönenbuch, Switzerland);
(2) a module for direct communication with the local
IBD team with guaranteed feedback within two working
days; and (3) a module with study questionnaires (quality
of life, drug adherence, absenteeism and health care
utilization). They will have six monthly health checks at
the outpatient clinic to monitor potential adverse effects
of the medication. In between these visits teenagers re-
ceive alerts to use the flarometer.
The frequency of use depends on the previous flarom-
eter score (Figure 1). When the score is in the high (red)
or moderate (orange) risk stratum, next flarometer use
is advised after one month. In the low (green) risk
stratum an alert to use the flarometer will be sent in
three months. Teenagers have the freedom to use the
flarometer more often, but fecal samples can only be
sent once a month. In case the flarometer is not used
despite three reminders (text or e-mail message), the
IBD-nurse will contact the teenager by phone.
Both teenager and local IBD team will receive a
computer-generated e-mail with the flarometer result,
which also includes treatment advice. In the high (red)
risk stratum the teenager is advised to contact the local
IBD-team for treatment intensification. In case the teen-
ager fails to contact the IBD-team, the IBD-nurse will
instead call the teenager. In the low (green) risk stratum
maintenance therapy remains unchanged. The inter-
mediate (orange) risk stratum requires evaluation of an
imminent relapse, drug adherence and potential inter-
current gastrointestinal infections.
The local IBD-team has the freedom to ignore the fla-
rometer treatment advice, but this should be well-founded
and indicated in the patient file. The web-assisted algorithm
is certainly not meant to replace the pediatrician. It is
intended to guide both pediatricians and patients in joint
decisions whether or not to intensify treatment by provid-
ing more objective estimates of probability, as a supplement
to other relevant clinical information. Any therapeutic
intervention remains the responsibility of the treating
pediatric gastroenterologist.
Interventions—modifications
Study participants from both groups are instructed to
contact their doctor immediately to report clinical de-
terioration between regular health checks, or if at any
time they want a consultation (side effects, other health
related questions). Rapid access to specialist care is guar-
anteed for both groups. All unscheduled health visits
(including those at the IBD clinic, general physician and
emergency department) and hospital admissions are
documented in the study data tracking system and are
reported as adverse events. Crosschecking will be done
by comparing doctor reported health consumption and
patient-reported health consumption.
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any reason if they wish to do so without any conse-
quences. The local principal investigator can decide to
withdraw a teenager from the study for urgent medical
reasons. Another patient from the same center may then
be randomized to enter the study.
Patients withdrawn from the experimental arm of the
trial will continue with usual care, outside the scope of
this study, as would have happened otherwise. Patients
who receive usual care and withdraw from the study will
continue to receive usual care as before entering the
study.
Interventions—adherence
In this trial adherence refers to the degree to which pa-
tients and IBD-team act in accordance with the flaro-
meter advice. Low adherence can have a substantial
effect on statistical power and interpretation of the trial
results. To help avoid these potential detrimental effects
of non-adherence, we have implemented the following
procedures: (1) screening candidate participants for having
an unfavourable disease course, as this may be a proxy for
non-adherence; (2) reminding study participants automa-
tically that the next flarometer score is due; (3) contacting
non-responders by telephone after two weeks of passivity;
(4) informing both patient and local IBD-team about the
flarometer treatment advice; (5) documenting ignored red
alerts (i.e. failing to intensify treatment despite flarometer
score in high risk stratum); and (6) restricting the statis-
tical analyses to those participants who replied to more
than 80 % of the alerts to use the flarometer.
Outcomes
The primary endpoint is the frequency of relapse rate
during a 52-week follow-up period. Investigators, health
providers and patients cannot be blinded to the assigned
intervention. To minimize bias the primary endpoint is
strictly defined as a clinical activity index score >10 points
(see Table 1), necessitating steroid therapy, a six-week
course of exclusive enteral nutrition, aminosalicylate dose
escalation, or introduction of anti-TNF antibodies (inflixi-
mab or adalimumab). We will calculate Kaplan-Meier
curves for both assignment groups. Time-to-relapse will be
compared with a two-sided logrank test. The hazard ratio
with its 95 % confidence interval for relapse will beTable 1 Translation of clinical score systems to Physician’s
Global Assessment
Physician Global Assessment PCDAI [7] shPCDAI [14, 38] PUCAI [8]
Remission <10 <10 <10




Severe activity >40 ≥65provided with a Cox proportional hazards (multivariate) re-
gression analysis. Potential confounding factors, including
age at diagnosis, type of IBD, date of last relapse, emotional
maturity and level of education, will be included in the Cox
proportional hazards model.
We are collecting data from a range of secondary end-
points, including the IMPACT-III score. This is a disease-
specific quality of life score, composed of 35 items on 6
domains: IBD-related symptoms (7 items), systemic symp-
toms (3), emotional functioning (7), social functioning (12),
body image (3) and treatment/intervention-related con-
cerns (3) [25, 26]. Each item is scored on a 5 point Likert
scale, coded from 0 to 4 points. Higher scores indicate bet-
ter quality of life. The IMPACT questionnaire is validated
for use in children eight years old and older and is recom-
mended for the evaluation of new therapies because of its
high sensitivity to change. The IMPACT-III (NL) is a trans-
lated and modified version of the original Canadian ques-
tionnaire that used a visual analogue scale [27, 28]. The
Likert scale was introduced as it has been shown that chil-
dren consider it easier to complete than a visual analogue
scale [29]. To compare the difference of IMPACT-scores
from baseline to final visit Student’s t-test or analysis of
variance will be used where appropriate. Other secondary
endpoints include the number of unscheduled health visits,
hospital admissions, IBD-related absenteeism from school
or parental work, and drug adherence, using the Morisky
Medication Adherence Scale (Fig. 3) [30].
The outcome parameter of the economic evaluation is
the number of relapses within one year. With this out-
come parameter, the incremental cost-effectiveness ratio
provides information to guide preference of the web-
assisted calprotectin-based treatment algorithm over
usual care. The time horizon of the evaluation will be
from randomization to the end of the study. Uncertainty
surrounding cost-effectiveness ratio will be explored by
bootstrap replication and by varying the major cost com-
ponents. Discounting will not be applied. The economic
evaluation will be performed from a societal perspective,
incorporating costs of travel to the hospital and costs of
leave from work of the parents, as well as direct medical
costs of IBD care (costs of medication, outpatient visits).
Questionnaires will be used to collect data regarding
health care consumption, travel and time costs and
productivity loss at study entry and at one-month inter-
vals thereafter. Other relevant data regarding health care
consumption such as number of contacts or visits with
the local IBD team, unscheduled health visits, hospital
admissions, and drug use will be recorded or collected
from existing hospital databases. Unit prices will be de-
termined according to Dutch guidelines. Standard prices
will be used if available and applicable, according to the
type of hospital where the patient is treated. Productivity
loss will be calculated using the friction cost method.
Fig. 3 IBD-live schedule of enrollment, interventions, and assessments. Comparability between groups will be assessed by summarizing emotional
maturity (Bar-On EQI:JV), quality of life (IMPACT-III), and drug adherence (Morisky Medication Adherence Scale, MMAS). All of these questionnaires
will be completed at home within one week after enrollment
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come analysis and provides an estimate of the relation-
ship between the difference in quality of life and the
difference in costs of both treatments. At the end of the
observation period we will evaluate the teenagers and
caretakers in the intervention group for their attitude to-
wards E-health.
Other study parameters
Emotional maturity may be a risk factor for poor adher-
ence and is therefore assessed at the start of the study
using the Bar-On Emotional Quotient Inventory (Youth
Version) [31]. Emotional maturity as well as the level of
education of patients and parents are to be used as covari-
ables in the final data analyses. Stool samples will also be
tested for colon pathogens (Salmonella enterica, Campylo-
bacter jejuni, Shigella spp/EIEC, Giardia lamblia, STEC)
and parasites (Cryptosporidium spp, Dientamoeba fragilis,
Entamoebe histolytica) with the real-time multiplex PCRs,
to control for false positive fCal values [32, 33].
Participant timeline
Teenagers who are potentially eligible based on inclusion
criteria will be identified and informed about the trial bythe local IBD team. In case the teenager is interested in
participation an information pack will be sent by mail,
containing a patient invitation letter, a participant infor-
mation sheet and consent forms. Patients who do not
participate due to exclusion criteria or refusal will be an-
onymously recorded, including patient characteristics
and, if available, the reason for non-participation.
During the outpatient appointment the health provider
will (1) recheck whether the participant has daily access to
a smartphone or tablet or an internet connection, (2) as-
sess whether the last relapse was more than three months
before, and (3) identify parents or legal guardians. After
written informed consent has been obtained, but before
randomization occurs, each patient will undergo a detailed
assessment (Fig. 3). Data collected will include demo-
graphic information (including travel time to clinic, level
of education of both patient and parents), clinical and
IBD-specific history (including age at diagnosis, type of
IBD, disease location, date of last relapse and current
maintenance treatment). The (pediatric) gastroenterologist
will perform a general physical examination (including
measurements of height and weight, and assessment of
pubertal maturation) and will rate the current disease ac-
tivity by using the PCDAI or PUCAI.
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be evaluated at the local trial site at six and twelve
months for disease activity (by physician rated PUCAI
or PCDAI), serological markers of inflammation and
fCal. Each participant will complete a diary for school-
absenteeism and parental absence from work once every
month, and IMPACT-III and MMAS questionnaires at
six and twelve months. Reminders will be sent by email,
with a direct link to the online questionnaires.
In between scheduled health visits teenagers assigned
to the experimental group receive alerts to use the on-
line flarometer and to send a feces sample by pre
stamped return envelope for fCal rapid analysis. Teen-
agers assigned to usual care may have outpatient ap-
pointments at three and nine months, depending on the
health check interval prior to participation.
Sample size
In earlier versions of the study protocol (v1 to v5) the pri-
mary outcome was defined as the number of relapses per
group during a 52-week follow-up. The nul-hypothesis
was based on a relapse rate of 40 % in the control group
[34], whereas the alternative hypothesis stated that in the
experimental group this percentage would drop down to
25 % [13]. We wished to detect this difference by a two-
sided test at 5 % level of significance with a probability of
80 %. With the binary outcome (event or not) 152 patients
per group were needed.
Accumulating data from the study as it continued
allowed re-estimating the sample size. Adapting the pri-
mary outcome from ‘number of events’ to ‘time-to-event’
per group could reduce the required sample size. To de-
tect a 15 % reduction in the absolute relapse risk after
52 weeks of follow-up with a two-sided significance level
of 5 % and with 80 % power, we calculated that we need
90 patients per group (taking into account a maximum
of 10 % loss-to-follow-up).Randomization and masking
Eligible patients for whom consent or assent is provided
will be allocated in a 1:1 ratio to the two arms of the study
according to a computer-generated random sequence
stratified by research site and disease type (Crohn’s disease
vs. ulcerative colitis), and using blocks of variable size.
The allocation sequence is generated by the biostatistics
unit of the UMCG, and is not available to any member of
the research team. Allocation concealment will be en-
sured, as the study website (https://www.ibd-live.nl) will
not release the randomization code until the teenager has
been recruited into the trial, which takes place after all
baseline measurements have been completed. The nature
of the intervention does not allow blinding of participants,
care providers, or outcome assessors.Retention
Once a teenager is randomized, the study site will make
every reasonable effort to follow the patient for the en-
tire study period of 52 weeks. It is projected that the rate
of loss-to-follow-up will be at most 10 %. Retention will
be promoted by sending automated reminders to the
participants in the experimental study arm to use the
flarometer, careful planning of outpatient appointments
to avoid school calendar breaks, and facilitating stool
collection with feces collection papers. Questionnaires
will be completed digitally via a hyperlink sent by email,
which will further limit participant burden.
There will be no explicit incentive for study partici-
pants. Participation in a child friendly website may be
perceived as an incentive, but it is not an incentive in a
material sense. Teenagers in the experimental arm will
have access to the website, while the controls will only
have access to the study questionnaires.
A participant who withdraws consent for follow-up assess-
ment of any of the secondary outcomes will be given the op-
tion to continue with assessments for the primary outcome.
Confidentiality and data management
Consecutive patients participating in the study will re-
ceive a unique study number. All data will be entered
electronically and stored linked to this study number.
Patients will complete digital questionnaires via a hyper-
link sent by email, which will automatically be linked to
the corresponding study number. Patients with access to
the IBD-live website will use their username and pass-
word for identification/login. The username will be
linked to the unique study number in order to store all
data concerning flarometer results.
Local trial sites will have access to the flarometer data
of their own patients only. The coordinating investigator
in the UMCG and the webmaster are the sole persons
who have access to the full subject identification code
list in order to be able to link patient login-ID to the
corresponding study number.
Feces samples will be marked with a study number label
and sent to the Department of Laboratory Medicine at the
UMCG. fCal results will be uploaded on the website by
the coordinating investigator and will be visible to the in-
dividual patients and their local IBD team. After measure-
ment of fCal levels the residual material will be analyzed
for detection of microbial gut pathogens.
Data will be stored during the study period and until
15 years thereafter. When patients and their parents give
permission, residual feces will be stored for a maximum
period of 15 years for future diagnostic research.
Statistical methods
The statistical analysis will be coordinated by a sta-
tistician from the biostatistics unit of the UMCG. The
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to-treat basis. All teenagers recruited into the study will
be included in these analyses; patients will be analyzed
within the group (IBD-live or usual practice) to which
they were randomized irrespective of what care they ac-
tually received. Where appropriate, secondary analyses
will be conducted using a per protocol basis. These ana-
lyses will be restricted to just those teenagers who replied
to more than 80 % of the alerts to use the flarometer and
to the teenagers in the control group who replied to more
than 80 % of the requests to send a stool sample for fCal
measurement.
As earlier published web-based programs have focussed
on patients with ulcerative colitis [17, 35, 36], we made an
a priori decision to do a subgroup analysis to examine the
intervention in two subtypes of IBD (ulcerative colitis and
Crohn’s disease). We will use a test of interaction to
examine whether the treatment effect differs between
these subgroups. In case of random missing data mul-
tiple imputation will be performed using the hot deck
method [37].
Data monitoring
A Data Safety Monitoring Board (DSMB) has been es-
tablished. The Chair of the DSMB is Dr. Nic Veeger (epi-
demiologist at the University Medical Centre Groningen),
with Dr. Hans Burgerhof (statistician, UMCG), and
Dr. Gieneke Gonera-de Jong, paediatrician at Wilhelmina
Hospital Assen). The Charter and responsibilities of the
DSMB are available on request from the IBD-live study
office. The DSMB is independent of the study orga-
nizers. During the period of recruitment to the study,
one interim analysis will be supplied, in strict confi-
dence, to the DSMB, together with any other analyses
that the committee may request. In the light of this in-
terim analysis, the DSMB will advise the trial steering
committee if, in its view, the active intervention has
been proved, beyond reasonable doubt, to be different
from the control (usual practice) for all participants.
The trial steering committee can then decide whether
or not to modify intake to the trial. The advice of the
DSMB will only be sent to the sponsor of the study.
Should the sponsor decide not to fully implement the
advice of the DSMB, the sponsor will then send the ad-
vice to the reviewing Medical Ethical Committee
(MEC), including a note to substantiate why (part of )
the advice of the DSMB will not be followed.
Premature termination of the study
An interim safety analysis will be performed after the
first 50 participants in both arms have completed the
first six months of the study. The interim-analysis will
be performed by the trial statistician. This will be based
on the number of clinical relapses, a significantdifference in IBD-associated hospital admissions and/or
emergency visits and/or unscheduled health visits, to the
detriment of the intervention group (IBD-live). As we
expect a non-normal distribution, the Mann–Whitney U
test will be used to test the differences that may have oc-
curred. As it may be hard to show a statistically signifi-
cant difference due to the sample size we propose a
composite-core as proxy for severity of clinical deterior-
ation of IBD during the study, based on objective pa-
rameters. In this score an unscheduled health visit = 1
point, an emergency visit = 2 points, and a hospital ad-
mission = 4 points. Given a sample size of n = 50, an α
of 0.05 (two-tailed) and an estimated standard deviation
of 4 points, we can reliably show a difference of 3 points
on the composite-score, which equals one hospital
admission.
Harms
This trial should be regarded as therapeutic research, as
two different treatment strategies are compared. Patients
allocated to usual care will receive IBD care as before.
There is no additional risk in this group. Patients in the
experimental arm will have fewer scheduled encounters
with their local IBD team, and blood drawings will be re-
duced to once every six months. This relatively long
interval between two phlebotomies may hinder early rec-
ognition of adverse drug reactions, although it is not un-
common for teenagers with quiescent IBD to have only
two blood drawings per year. Patients from both groups
are instructed to contact the local IBD-team if they ex-
perience relapse, or if at any time they want a consult-
ation. The management of relapses is not changed from
the current routine practice and is the same for both
groups.
In this trial an adverse event will be defined as any
undesirable experience occurring to a participant dur-
ing the study, whether or not considered related to
the experimental intervention, including any unsched-
uled health visit. Adverse events will be collected
after the participant has provided consent and en-
rolled in the study. If an adverse event is experienced
within one month after the enrollment visit, the event
will be reported as not related to the trial. All adverse
events occurring later than one month after enroll-
ment will be recorded. An adverse event that meets
the criteria for a serious adverse event between study
enrollment and hospital discharge will be reported to
the local MEC.
Ethics
The trial will be conducted according to the principles
of the Declaration of Helsinki (59th version, October
2008) and in accordance with the Dutch Medical
Research Involving Human Subjects Act (WMO). The
Heida et al. Trials  (2015) 16:271 Page 9 of 10independent Medical Ethical Committee (MEC) of the
University Medical Centre Groningen (Groningen, the
Netherlands) has approved the study protocol.
Secondary approval was obtained from the boards of the
Academic Medical Centre (Amsterdam), Erasmus Medical
Centre (Rotterdam), Haga Hospital (Den Haag), Isala
Hospital (Zwolle), Leiden University Medical Centre
(Leiden), Medisch Spectrum Twente (Enschede), Rijnstate
Hospital (Arnhem), University Medical Centre Utrecht
(Utrecht), and VU medical center (Amsterdam) according
to the Dutch CCMO External Review Directive 2012
(RET 2012).
Any modifications to the protocol which may impact
on the conduct of the study, potential benefit of the pa-
tient or may affect patient safety, including changes of
study objectives, study design, patient population, sam-
ple sizes, study procedures, or significant administrative
aspects will require a formal amendment to the protocol.
Such amendment will be approved by the MEC prior to
implementation and notified to the participating centers.
Written informed consent will be obtained from both
parents or legal guardians of all participants younger
than 18 years old, and from all teenagers 12- to 19-years
old, prior to randomization. The trial is registered in the
Dutch Trial Register (http://www.trialregister.nl/trialreg/
index.asp) with identification number NTR3759.
Discussion
This trial will test the use of remission induction therapy
delivered according to a web-assisted calprotectin-based
treatment algorithm head-to-head against the same
treatment based on physician assessment of individual
patient characteristics.
We expect that use of IBD-live will result in better dis-
ease control, expressed as a lower relapse rate, accom-
panied by lower costs of disease management as compared
to usual care. The number of scheduled outpatient visits is
expected to drop by 50 %, unscheduled visits for uncer-
tainty concerning suspected relapse will probably reduce in
number, and the number of unscheduled visits for confirmed
relapse are also expected to drop by 50 %. The physician’s
workload is expected to decrease, while the nurse’s workload
is expected to increase. Combined with the expected drop in
relapse frequency, this could mean that IBD-live is the
dominant strategy in the cost-effectiveness analysis.
Relevance for practice/implementability
IBD-live care corresponds to the needs and wishes of both
patients and clinicians. Unnecessary, but time-consuming
visits to the clinic are reduced, while the quality of disease
monitoring is maintained or even improved. Scientific
societies and patient associations broadly support the
concept of tailor-made IBD-management, and health in-
surance companies are co-financing this scientific project.If IBD-live care proves to be effective, funding for this
type of long-term care will be provided under the Excep-
tional Medical Expenses Act (AWBZ). The trial will yield
information on disease monitoring with fCal, which has
hitherto been a gap in both national and international
guidelines. Study results will eventually be included in
Dutch and international guidelines.
Additional value of the study
Pediatricians have so far always been reluctant to allow
teenagers in the driving seat. Now that reliable non-
invasive predictors of relapse have become available,
home monitoring may be a feasible concept. If IBD-live
care proves to be effective, this would mean a funda-
mental change in approach.
Treatment intensification in teenagers who are doing
well, but who have a high risk of progression to clinically
overt relapse, is currently not recommended. Periodically
measuring fCal levels may facilitate recognition of pre-
clinical relapse. The trial described in this protocol will
allow us to determine whether preemptive treatment of
teenagers with increased fCal levels, but who report no
complaints, really prevents progression to symptomatic
relapse. This could be the second paradigm shift.
Trial status
Recruitment began on 6 June 2013. It is anticipated that
study recruitment will be completed by 30 September
2015, and that the trial will conclude by 30 September
2016.
Abbreviations
CRP: C-reactive protein; DSMB: Data Safety Monitoring Board; fCal: Fecal
calprotectin; IBD: Inflammatory bowel disease; MEC: Medical Ethical
Committee; MMAS: Morisky Medication Adherence Scale; PCDAI: Pediatric
Crohn’s Disease Activity Index; PUCAI: Pediatric Ulcerative Colitis Activity
Index; shPCDAI: Short version of the PCDAI; TNF: Tumor necrosis factor;
UMCG: University Medical Centre Groningen.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PvR conceived of the study. AH, HG, AMK, HJV, and PvR initiated the study
design, and AD helped with implementation. PvR is the grant holder.
HG provides statistical expertise in clinical trial design and cost-effectiveness.
AH is conducting the primary statistical analysis. All authors contributed to
refinement of the study protocol. All authors read and approved the final
manuscript.
Acknowledgements
This study is funded by ZonMw Health Care Efficiency Research, Innovation
Fund Dutch Insurance Companies, and NutsOhra Fund. Reagents for the
Quantum Blue® calprotectin point-of-care tests were donated by Bühlmann
Laboratories AG (Schönenbuch, Switzerland). A start-up grant (€ 15,000.-) for
the development of the web-based program IBD-live was awarded by
Ferring Pharmaceuticals BV (Hoofddorp, the Netherlands), producer of
PENTASA® mesalazine. Neither company had a role in the design of this
study and will not have any role during its execution, analyses, interpretation
of the data, or decision to submit results.
Heida et al. Trials  (2015) 16:271 Page 10 of 10Author details
1Department of Pediatric Gastroenterology, University of Groningen,
University Medical Centre Groningen, PO Box 30001, 9700, RB Groningen,
The Netherlands. 2Department of Clinical Epidemiology (Medical Technology
Assessment), University of Groningen, University Medical Centre Groningen,
Hanzeplein 1, 9713, GZ Groningen, The Netherlands. 3Department of
Laboratory Medicine, University of Groningen, University Medical Centre
Groningen, Hanzeplein 1, 9713, GZ Groningen, The Netherlands.
Received: 28 April 2015 Accepted: 29 May 2015References
1. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best
Pract Res Clin Gastroenterol. 2004;18:509–23.
2. Henderson P, Hansen R, Cameron F, Gerasimidis K, Rogers P, Bisset W, et al.
Rising incidence of pediatric inflammatory bowel disease in Scotland.
Inflamm Bowel Dis. 2012;18:999–1005.
3. Benchimol E, Fortinsky K, Gozdyra P, Van Den Heuvel M, Van Limbergen J,
Griffiths A. Epidemiology of pediatric inflammatory bowel disease: a systematic
review of international trends. Inflamm Bowel Dis. 2011;17:423–39.
4. Ashton JJ, Wiskin AE, Ennis S, Batra A, Afzal NA, Beattie RM. Rising incidence
of paediatric inflammatory bowel disease (PIBD) in Wessex, Southern
England. Arch Dis Child. 2014;99:659–64.
5. Romberg-Camps M, Hesselink-van de Kruijs M, Schouten L, Dagnelie P,
Limonard C, Kester A, et al. Inflammatory bowel disease in South Limburg
(the Netherlands) 1991–2002: incidence, diagnostic delay, and seasonal
variations in onset of symptoms. J Crohn’s Colitis. 2009;3:115–24.
6. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical
implications of mucosal healing for the management of IBD. Nat Rev
Gastroenterol Hepatol. 2010;7:15–29.
7. Hyams J, Ferry G, Mandel F, Gryboski J, Kibort P, Kirschner B. Development
and validation of a pediatric Crohn’s disease activity index. J Pediatr
Gastroenterol Nutr. 1991;12:439–47.
8. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al.
Development, validation, and evaluation of a pediatric ulcerative colitis
activity index: a prospective multicenter study. Gastroenterology.
2007;133:423–32.
9. Westwood N, Travis SP. Review article: what do patients with inflammatory
bowel disease want for their clinical management? Aliment Pharmacol Ther.
2008;27 Suppl 1:1–8.
10. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful,
magic, or unnecessary toys? Gut. 2006;55:426–31.
11. Chung-Faye G, Sandhu K, Logan RP, Sherwood RA. Fecal calproctectin is
strongly predictive of clinical disease activity and histological severity in
inflammatory bowel disease. Gastroenterology. 2011;140:S421.
12. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening
of patients with suspected inflammatory bowel disease: diagnostic
meta-analysis. BMJ. 2010;341:c3369.
13. Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in
teenagers with inflammatory bowel disease who report full disease control.
Inflamm Bowel Dis. 2012;18:2018–25.
14. Kappelman MD, Crandall WV, Colletti RB, Goudie A, Leibowitz IH, Duffy L,
et al. Short pediatric Crohn’s disease activity index for quality improvement
and observational research. Inflamm Bowel Dis. 2011;17:112–7.
15. Escher JC, Hagemeijer JW, de Ridden L, Rings EHHM, et al. Guideline
on diagnosis and treatment of pediatric IBD. 2008. Available from:
http://www.nvk.nl/Portals/0/richtlijnen/inflammatoire%20darmziekten/
inflammatoiredarmziekten.pdf. Accessed on 1 April 2015.
16. Van Groningen J, Arnold J, Fishman L. When independence develops in
adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr.
2009;49:E57.
17. Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P. Development of a
Web-based concept for patients with ulcerative colitis and 5-aminosalicylic
acid treatment. Eur J Gastroenterol Hepatol. 2010;22:695–704.
18. Chan DS, Callahan CW, Hatch-Pigott VB, Lawless A, Proffitt HL, Manning NE,
et al. Internet-based home monitoring and education of children with
asthma is comparable to ideal office-based care: results of a 1-year asthma
in-home monitoring trial. Pediatrics. 2007;119:569–78.19. Lehmkuhl HD, Storch EA, Cammarata C, Meyer K, Rahman O, Silverstein J,
et al. Telehealth behavior therapy for the management of type 1 diabetes
in adolescents. J Diabetes Sci Technol. 2010;4:199–208.
20. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with
non-adherence to oral medication for inflammatory bowel disease:
a systematic review. Am J Gastroenterol. 2010;105:525–39.
21. Gray WN, Denson LA, Baldassano RN, Hommel KA. Treatment adherence in
adolescents with inflammatory bowel disease: the collective impact of
barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol.
2012;37:282–91.
22. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the
outcomes of patients with quiescent ulcerative colitis. Am J Med.
2003;114:39–43.
23. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic
review: impact of non-adherence to 5-aminosalicylic acid products on the
frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther.
2009;29:247–57.
24. IBD working group of the European Society for Paediatric Gastroenterology,
Hepatology and Nutrition. Inflammatory bowel disease in children and
adolescents: recommendations for diagnosis–the Porto criteria. J Pediatr
Gastroenterol Nutr. 2005;41:1–7.
25. Loonen HJ, Grootenhuis MA, Last BF, Koopman HM, Derkx HH. Quality of
life in paediatric inflammatory bowel disease measured by a generic and a
disease-specific questionnaire. Acta Paediatr. 2002;91:348–54.
26. Loonen HJ, Grootenhuis MA, Last BF, de Haan RJ, Bouquet J, Derkx BH.
Measuring quality of life in children with inflammatory bowel disease: the
impact-II (NL). Qual Life Res. 2002;11:47–56.
27. Otley A, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, et al. The IMPACT
questionnaire: a valid measure of health-related quality of life in pediatric
inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35:557–63.
28. Griffiths AM, Nicholas D, Smith C, Munk M, Stephens D, Durno C. Development
of a quality-of-life index for pediatric inflammatory bowel disease: dealing with
differences related to age and IBD type. J Pediatr Gastroenterol Nutr.
1999;28:S46–52.
29. Van Laerhoven H, van der Zaag-Loonen HJ, Derkx BH. A comparison of
Likert scale and visual analogue scales as response options in children’s
questionnaires. Acta Paediatr. 2004;93:830–5.
30. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a
self-reported measure of medication adherence. Med Care. 1986;24:67–74.
31. Bar-On R, Parker J. Bar-On Emotional Quotient Inventory: Youth Version
(EQ-i:YV): technical manual. Toronto: Multi-Health Systems; 2008.
32. Sýkora J, Siala K, Huml M, Varvaovská J, Schwarz J, Pomahaová R. Evaluation
of faecal calprotectin as a valuable non-invasive marker in distinguishing
gut pathogens in young children with acute gastroenteritis. Acta Paediatr
Int J Paediatr. 2010;99:1389–95.
33. Van de Vijver E, Schreuder AB, Cnossen WR, Muller Kobold AC, van Rheenen PF.
Safely ruling out inflammatory bowel disease in children and teenagers without
referral for endoscopy. Arch Dis Child. 2012;97:1014–8.
34. Sipponen T, Björkesten CG, Färkkilä M, Nuutinen H, Savilahti E, Kolho K-L. Faecal
calprotectin and lactoferrin are reliable surrogate markers of endoscopic response
during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45:325–31.
35. Cross RK, Finkelstein J. Challenges in the design of a Home Telemanagement
trial for patients with ulcerative colitis. Clin Trials. 2009;6:649–57.
36. Cross R, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized,
controlled trial of home telemanagement in patients with ulcerative colitis
(UC HAT). Inflamm Bowel Dis. 2012;18:1018–25.
37. Streiner DL. The case of the missing data: methods of dealing with
dropouts and other research vagaries. Can J Psychiatry. 2002;47:68–75.
38. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al.
Mathematical weighting of the pediatric Crohn’s disease activity index
(PCDAI) and comparison with its other short versions. Inflamm Bowel Dis.
2012;18:55–62.
